Targeted therapy for advanced thyroid cancer — when iodine stops working

Targeted therapy is a type of medicine that blocks specific signals a cancer uses to grow and form new blood vessels. Most of these medicines for thyroid cancer belong to a group called kinase inhibitors, taken as a daily tablet. Unlike traditional chemotherapy, which affects fast-dividing cells broadly, targeted therapy aims at the particular pathways driving the cancer. It is used for advanced thyroid cancer — usually when surgery and radioactive iodine can no longer control the disease. It does not replace surgery or radioactive iodine for early cancer; it is an option for specific, more advanced situations decided by a tumour board.

Targeted therapy is considered only for advanced thyroid cancer, not for most people. It is mainly used when a differentiated cancer has stopped responding to radioactive iodine, for some advanced medullary thyroid cancers, and for selected anaplastic cancers. The decision depends on the type, the stage, the results of biomarker testing, and your overall health. Most people with thyroid cancer are treated well with surgery and radioactive iodine and never need these advanced thyroid cancer drugs. A specialist confirms the type and stage first, then a tumour board decides together whether targeted therapy is the right next step.

Chemotherapy affects rapidly dividing cells throughout the body, while targeted therapy aims at specific molecules and pathways the cancer depends on. For advanced thyroid cancer, targeted therapy — usually a kinase inhibitor tablet — is generally preferred over traditional chemotherapy, which often does not work well for thyroid cancer. Because it is more focused, the side-effect pattern is different from chemo, though it still needs careful monitoring. Targeted therapy is taken at home as a daily tablet rather than given as repeated infusions. A tumour board decides which approach fits each person's type, stage, and health.

Most targeted therapy for thyroid cancer is taken as a daily tablet at home, not by drip. Before starting, the team confirms the type and stage and may run biomarker testing to check which pathway is driving the cancer. You are then reviewed regularly so the dose can be adjusted and any side effects managed early. Treatment usually continues for as long as it keeps the cancer controlled and is tolerated well. Because it is an ongoing tablet, clear instructions, regular blood pressure and blood checks, and easy access to your team matter — which is why a doctor-led, well-monitored plan is important.

A kinase inhibitor is a class of targeted therapy tablet that blocks enzymes called kinases, which the cancer uses to signal, grow, and build new blood vessels. In thyroid cancer, kinase inhibitors are the most common form of targeted therapy for advanced disease. By interrupting these signals, they can slow or shrink cancers that no longer respond to radioactive iodine. They do not cure advanced thyroid cancer, but they can help control it and relieve symptoms for many people. Which medicine suits you depends on the type, biomarker results, and your overall health — a decision made by the tumour board, not assumed.

Side effects vary between medicines, but common ones include tiredness, raised blood pressure, diarrhoea, changes to the skin on the hands and feet, mouth soreness, and weight loss. Most are manageable when caught early, which is why regular monitoring and dose adjustments are part of the plan. Some people need their dose lowered or paused for a time. Telling your team about new symptoms quickly helps keep treatment on track and comfortable. At CION, we explain what to watch for, check you regularly, and adjust care to keep side effects low while keeping the cancer controlled — with no unnecessary tests.

At CION, advanced thyroid cancer is reviewed by a tumour board — surgical, medical, and radiation oncologists deciding together rather than one doctor alone. They confirm the exact type and stage, review imaging, and use biomarker testing where it helps choose the right medicine. Targeted therapy is recommended only when it genuinely fits, and the reasons are explained clearly in a 45-minute consultation. This reflects our approach of decisions for healing, not billing, with transparent costs and no unnecessary treatment. You deserve to understand why a treatment is suggested before you start it.

Yes — because targeted therapy is for advanced thyroid cancer and is an ongoing treatment, it is reasonable to seek a specialist review or a second opinion before starting. A thyroid cancer specialist can confirm the type and stage, check whether radioactive iodine or other options still apply, and review biomarker results to choose the most suitable medicine. A free, written second opinion can give you clarity and confidence in the plan. At CION, a doctor-led team reviews your records and explains your options without pressure, so any decision you make is an informed one.